All News
Filter News
Found 8,079 articles
-
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
11/8/2023
Aclarion, Inc. announced that they have successfully achieved their goal of enrolling ten leading spine surgery KOLs to assist the company in driving Nociscan to standard of care for identifying discogenic low back pain.
-
Nyxoah Reports Third Quarter 2023 Financial and Operating Results
11/8/2023
Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, reported financial and operating results for the third quarter of 2023.
-
The cell therapy-focused biotech will use most of the net proceeds from its initial public offering to fund Phase II clinical trials for its lead program, a novel CAR T-cell candidate.
-
Nyxoah to Participate in the 2023 Jefferies London Healthcare Conference
11/7/2023
Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced that the Company will participate in the Jefferies London Healthcare Conference, which takes place November 14 – 16, 2023 in London.
-
The New York-based genetic medicine company, which expects gross proceeds of approximately $100 million, joins a small group of biotechs that have launched initial public offerings this year.
-
ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment
11/2/2023
ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for cancer, announced the addition of multiple industry veterans to its leadership team to support its growth.
-
Bausch Health Announces Third-Quarter 2023 Results
11/2/2023
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third-quarter 2023 financial results and other key updates from the quarter.
-
Evolent Announces Third Quarter 2023 Results
11/2/2023
Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended September 30, 2023.
-
The biotech venture capital firm, led by former Andreessen Horowitz senior partner Kouki Harasaki, emerged from stealth on Wednesday focused on investing in companies with first-in-class or best-in-class therapies.
-
Nonalcoholic Steatohepatitis (NASH) Market to Observe Stunning Growth by 2032 Owing to a Robust Pipeline
11/1/2023
The NASH market is expected to evolve because of emerging therapies like MGL-3196, Semaglutide, Vonafexor, HPG1860, VK2809, BIO89-100, LPCN 1144, and others.
-
Gate Bioscience Emerges from Stealth and Introduces Molecular Gates, a New Class of Small Molecule Therapeutics
11/1/2023
Gate Bioscience, a biotechnology company creating a new class of medicines called Molecular Gates, unveiled the company and its scientific platform.
-
Bioluminescence Ventures Emerges from Stealth with $477M AUM
11/1/2023
Bioluminescence Ventures today announced its emergence from stealth with $477M in assets under management across two funds: Bioluminescence Ventures Fund I, L.P., and Bioluminescence Ventures Fund II, L.P.
-
Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance
11/1/2023
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2023 financial results.
-
Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
10/31/2023
Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Christopher Riley has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Biotechnology business, effective January 1, 2024.
-
iNtRON, Executes Evaluation License and Option Agreement for SAL200
10/31/2023
iNtRON Biotechnology has announced that they have signed an "EVALUATION LICENSE AND OPTION AGREEMENT" with Basilea Pharmaceutica Ltd, Allschwil, granting Basilea the option to enter into an exclusive license agreement for the antibacterial bio-drug SAL200.
-
With the potential FDA approval of an MDMA-based therapy for PTSD on the horizon, biopharma stakeholders are eyeing psychedelics with fresh anticipation.
-
Rapport Therapeutics Appoints Chief Financial Officer
10/30/2023
Rapport Therapeutics, Inc. today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.
-
Mozart Therapeutics Expands Executive Leadership Team with Appointments of Dr. Jason Chien, Chief Medical Officer, and Russ Hawkinson, Chief Financial Officer
10/30/2023
Mozart Therapeutics today announced the expansion of its executive leadership team with the appointments of Jason Chien , MD, as Chief Medical Officer, and Russ Hawkinson as Chief Financial Officer.
-
Evecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot Ehrich
10/30/2023
Evecxia Therapeutics, Inc. today announced the appointments of Allan L. Shaw and Elliot Ehrich, MD to its Board of Directors, bringing with them decades of leadership experience in the biopharmaceutical industry.
-
Xencor Announces Planned Retirement of Chief Financial Officer John Kuch
10/26/2023
Xencor, Inc. announced that John J. Kuch, senior vice president and chief financial officer, plans to retire in March 2024, after a 23-year career with Xencor and over 40 years in corporate finance.